...
首页> 外文期刊>Nephrology. >Sphingosine-1-phosphate reduces hepatic ischaemia/reperfusion-induced acute kidney injury through attenuation of endothelial injury in mice.
【24h】

Sphingosine-1-phosphate reduces hepatic ischaemia/reperfusion-induced acute kidney injury through attenuation of endothelial injury in mice.

机译:1-磷酸鞘氨醇通过减轻小鼠内皮损伤来减轻肝缺血/再灌注引起的急性肾损伤。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aim: Hepatic ischaemia/reperfusion injury (IRI) frequently complicates acute kidney injury (AKI) during the perioperative period. This study was to determine whether hepatic IRI causes AKI and the effect of the sphingosine-1-phosphate (S1P) on AKI. METHODS: S1P and vehicle were given to mice before ischaemia and mice were subjected to hepatic IRI. Plasma creatinine (PCr), alanine transaminase (ALT), urinary neutrophil gelatinase-associated lipocalin (NGAL) and renal histological changes were determined. As a marker of endothelial injury, vascular permeability was measured. The effect of VPC 23019, a S1P(1) receptor antagonist, was also assessed. RESULTS: Hepatic IRI resulted in liver injury (increased ALT) and systemic inflammation. Kidneys showed elevated inflammatory cytokines, leucocyte infiltration, increased vascular permeability, tubular cell apoptosis and increased urinary NGAL, although PCr did not increase. Pretreatment with S1P resulted in an attenuation of systemic inflammation and kidney injury without any effect on plasma ALT or peripheral lymphocytes. The protective effect of S1P was partially reversed by VPC 23019, suggesting the important contribution of the S1P/S1P(1) pathway to protect against hepatic IRI-induced AKI. CONCLUSION: The study data demonstrate the important contribution of systemic inflammation and endothelial injury to AKI following hepatic IRI. Modulation of the S1P/S1P(1) receptor pathway might have some therapeutic potential in hepatic IRI-induced kidney injury.
机译:目的:围手术期肝缺血/再灌注损伤(IRI)经常使急性肾损伤(AKI)复杂化。这项研究是为了确定肝IRI是否会引起AKI,以及1-磷酸鞘氨醇(S1P)对AKI的影响。方法:在缺血前给小鼠S1P和赋形剂,并对小鼠进行肝IRI。测定血浆肌酐(PCr),丙氨酸转氨酶(ALT),尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和肾脏组织学变化。作为内皮损伤的标志物,测量了血管渗透性。还评估了VPC 23019(一种S1P(1)受体拮抗剂)的作用。结果:肝IRI导致肝损伤(ALT增加)和全身性炎症。肾脏显示出炎性细胞因子升高,白细胞浸润,血管通透性增加,肾小管细胞凋亡和尿液NGAL升高,尽管PCr并未升高。 S1P预处理可减轻全身炎症和肾脏损伤,而对血浆ALT或外周淋巴细胞没有任何影响。 VPC 23019可以部分逆转S1P的保护作用,表明S1P / S1P(1)通路对预防肝IRI诱导的AKI的重要贡献。结论:研究数据表明,系统性炎症和内皮损伤对肝IRI后AKI的重要贡献。 S1P / S1P(1)受体途径的调节可能在肝IRI诱发的肾损伤中具有某些治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号